Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL) – Japan
jRCT2080224852Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and cardiac morbidity comparing Semaglutide with Placebo / control (2 arms). Started Sep 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on jRCT2080224852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224852.